

# Michele Ardolino

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9150983/michele-ardolino-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24  
papers

1,892  
citations

14  
h-index

27  
g-index

27  
ext. papers

2,416  
ext. citations

9.1  
avg, IF

4.75  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 24 | When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.. <i>Science Advances</i> , <b>2022</b> , 8, eabj3286  | 14.3 | 3         |
| 23 | Muscle-specific deletion of SLK/Stk2 enhances p38 activity and myogenesis in mdx mice. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2021</b> , 1868, 118917        | 4.9  | 1         |
| 22 | Immunotherapy for sarcomas: new frontiers and unveiled opportunities <b>2021</b> , 9,   |      | 11        |
| 21 | Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 2568-2575                             | 6.1  | 6         |
| 20 | Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers. <i>Oncogene</i> , <b>2020</b> , 39, 4592-4602  | 9.2  | 4         |
| 19 | Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1512   | 8.4  | 83        |
| 18 | Is innate immunity our best weapon for flattening the curve?. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3954-3956   | 15.9 | 9         |
| 17 | Killers 2.0: NK cell therapies at the forefront of cancer control. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 3499-3510  | 15.9 | 84        |
| 16 | Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4654-4668  | 15.9 | 355       |
| 15 | Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness. <i>Journal of Immunology</i> , <b>2016</b> , 197, 4127-4136 | 5.3  | 3         |
| 14 | Immunosurveillance and immunotherapy of tumors by innate immune cells. <i>Current Opinion in Immunology</i> , <b>2016</b> , 38, 52-8  | 7.8  | 75        |
| 13 | Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors. <i>Oncolimmunology</i> , <b>2016</b> , 5, e1002725                                  | 7.2  | 8         |
| 12 | Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. <i>Cancer Discovery</i> , <b>2016</b> , 6, 630-49      | 24.4 | 257       |
| 11 | Recognition of tumors by the innate immune system and natural killer cells. <i>Advances in Immunology</i> , <b>2014</b> , 122, 91-128   | 5.6  | 233       |
| 10 | NK cell self tolerance, responsiveness and missing self recognition. <i>Seminars in Immunology</i> , <b>2014</b> , 26, 138-44   | 10.7 | 126       |
| 9  | Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 4781-94   | 15.9 | 120       |
| 8  | A role for host activation-induced cytidine deaminase in innate immune defense against KSHV. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003748  | 7.6  | 30        |

|   |  |      |     |
|---|--|------|-----|
| 7 | p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 2057-69           | 16.6 | 244 |
| 6 | Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire. <i>Blood</i> , <b>2013</b> , 121, 5025-33   | 2.2  | 26  |
| 5 | NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. <i>Frontiers in Immunology</i> , <b>2012</b> , 3, 408 | 8.4  | 46  |
| 4 | DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. <i>Blood</i> , <b>2011</b> , 117, 4778-86         | 2.2  | 96  |
| 3 | Modulation of T Cell-Mediated Immune Responses by Natural Killer Cells <b>2010</b> , 315-327   |      | 3   |
| 2 | Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. <i>Blood</i> , <b>2009</b> , 113, 2955-64                                | 2.2  | 52  |
| 1 | When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer   |      | 3   |